← Oncology Approval Tracker

FDA DECISION ·

Imfinzi + BCG

durvalumab with Bacillus Calmette–Guérin · AstraZeneca

FDA approvalNew or expanded indicationBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer.

LAMPGEN ANALYSIS

Why it matters

This combines systemic checkpoint therapy with intravesical BCG in a BCG-naïve high-risk population. It differs clinically from treatments used after BCG failure.

What research teams should watch

Track prior BCG exposure, risk-defining pathology and instillation completion. Coordinate urology surveillance with systemic immune-toxicity reporting.

PRIMARY RECORDS

Sources